For laboratory research only
Compare Thymosin alpha-1 research suppliers
Listings now default to lowest tracked price per mg. The highlighted price badge is a catalog-price signal only, not a quality, safety, or documentation ranking.
The document count covers six basic checks. “Not found” means we could not confirm it from the public records we reviewed—not that the testing never happened.
Affiliate disclosure: Some links may earn PDD a commission. Affiliate status does not change what we report or how suppliers are ordered.
Eppix Labs
5 of 6 fields documentedReview recommendedThymosin Alpha-1 (10 mg)
Exact name catalog match · No active affiliate relationship · Price badge is not an overall recommendation
Listed price
$54.99
$5.50 per mg
In stock
PS Peptides
5 of 6 fields documentedPossibly outdatedThymosin Alpha-1 (10 mg)
Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
$54.99
$5.50 per mg
Est. with PDD10: $49.49
$4.95/mg
In stock
Ascension Peptides
2 of 6 fields documentedPossibly outdatedThymosin alpha-1 (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$71.00
$7.10 per mg
In stock
Ascend Science
6 of 6 fields documentedReview recommendedThymosin Alpha-1 (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$75.00
$7.50 per mg
Est. with PDD: $63.75
$6.38/mg
In stock
Particle Peptides
2 of 6 fields documentedReview recommendedThymosin Alpha 1 (5 mg)
Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
€40.64
€8.13 per mg
In stock
How Thymosin alpha-1 is used in research
Thymosin alpha-1 is derived from prothymosin alpha and has been investigated for effects on innate and adaptive immune pathways.
Clinical research has been conducted internationally across several conditions. Regulatory authorization varies by country, and results from one disease context cannot be generalized to another.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Immune-cell studies examine dendritic, T-cell, and cytokine responses.
Animal
Host-response and disease models are reported.
Human
International clinical studies exist, but there is no FDA-approved U.S. drug.
What the evidence does not establish
The literature spans diverse populations, combinations, and endpoints, making broad claims unreliable.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Confirm the 28-residue sequence and N-terminal acetylation state.
- Immune assays require rigorous endotoxin controls.
- Verify the regulatory and manufacturing context of any cited clinical test article.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
Thymosin alpha-1 is not FDA-approved in the United States, although products may be authorized in other jurisdictions.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.